4.3 Letter

Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma

Sebastian Adeberg et al.

Summary: This study aimed to establish a robust DNA methylome-based classification system for glioblastoma patients with poor prognosis. The results showed that the SVZM classification provides an effective method for stratifying patients with poor prognosis and deciphering molecular mechanisms governing aggressive tumor phenotypes.

ACTA NEUROPATHOLOGICA (2022)

Article Oncology

A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets

Lin Wang et al.

Summary: Recent studies have shown that glioblastoma (GBM) lacks specific DNA mutations in recurrent disease, suggesting phenotype switching rather than genetic evolution as the mechanism of treatment failure. Using different assays, we analyzed GBM specimens and found a shift to a mesenchymal phenotype in recurrent GBMs mediated by activator protein 1. T-cell abundance at recurrence was prognostic and correlated with hypermutation status, and tumor-supportive networks involving GBM cells, nonmalignant neuroglia, and immune cells were identified.

NATURE CANCER (2022)

Article Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019

Quinn T. Ostrom et al.

Summary: The report provides the latest data on primary brain tumors in the United States, including incidence rates, mortality rates, and relative survival rates. The overall incidence rate is higher in females and non-Hispanic population, and glioblastoma is the most common malignant brain tumor, while meningioma is the most common non-malignant brain tumor. The relative survival rate is lower for malignant brain tumors and higher for non-malignant brain tumors.

NEURO-ONCOLOGY (2022)

Article Clinical Neurology

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts

Kristyn Galbraith et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2020)

Review Clinical Neurology

Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma

Timothy E. Richardson et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2020)

Review Biochemistry & Molecular Biology

Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma

Monica Fedele et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Article Multidisciplinary Sciences

Longitudinal molecular trajectories of diffuse glioma in adults

Floris P. Barthel et al.

NATURE (2019)

Review Pathology

Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics

Jose E. Velazquez Vega et al.

ADVANCES IN ANATOMIC PATHOLOGY (2018)

Article Multidisciplinary Sciences

DNA methylation-based classification of central nervous system tumours

David Capper et al.

NATURE (2018)

Article Genetics & Heredity

Clonal evolution of glioblastoma under therapy

Jiguang Wang et al.

NATURE GENETICS (2016)